CLRB
Cellectar
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CLRB Profile
Cellectar Biosciences, Inc.
A late-stage biopharmaceutical company focused on targeted treatments for cancer
100 Campus Drive, Florham Park, New Jersey 07932
--
Cellectar Biosciences, Inc., formerly known as Novelos Therapeutics, Inc., was founded in Delaware in June 1996. On February 11, 2014, the company changed its name to its current name. The company is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of cancer therapies. The company's core objective is to utilize proprietary phospholipid ether drug conjugate delivery platforms to develop PDCs that are designed to specifically target cancer cells and provide better efficacy and better safety due to fewer off-target effects.